Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis

The findings indicated that integrating PD-1/L1 blocking agents with SOC regimens for mCRC as first-line treatment failed to demonstrate significant improvements in ORR. Existing clinical data remain inadequate to establish OS advantages, particularly in patients with MSS/pMMR, despite exhibiting manageable toxicity profiles. Subsequent confirmation through rigorously designed phase III clinical trials remains essential to verify these therapeutic outcomes.